Markus Sperandio

Markus Sperandio

Auto-generated profile, based on publicly available information

Markus Sperandio

Walter Brendel Center of Experimental Medicine, Biomedical Center, Institute of Cardiovascular Physiology and Pathophysiology, Ludwig-Maximilians-University, Planegg-Martinsried

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Piero PortincasaPiero Portincasa
Piero Portincasa
LBLeonilde Bonfrate
Leonilde Bonfrate
Mirco VaccaMirco Vacca
Mirco Vacca
MAMaria De Angelis
Maria De Angelis
IFIlaria Farella
Ilaria Farella
ACAgostino Di Ciaula
Agostino Di Ciaula
Gut microbiota encompasses a wide variety of commensal microorganisms consisting of trillions of bacteria, fungi, and viruses. This microbial population coexists in symbiosis with the host, and related metabolites have profound effects on human health. In this respect, gut microbiota plays a pivotal role in the regulation of metabolic, endocrine, and immune functions. Bacterial metabolites include the short chain fatty acids (SCFAs) acetate (C2), propionate (C3), and butyrate (C4), which are the most abundant SCFAs in the human body and the most abundant anions in the colon. SCFAs are made from fermentation of dietary fiber and resistant starch in the gut. They modulate several metabolic pathways and are involved in obesity, insulin resistance, and type 2 diabetes. Thus, diet might influence gut microbiota composition and activity, SCFAs production, and metabolic effects. In this narrative review, we discuss the relevant research focusing on the relationship between gut microbiota, SCFAs, and glucose metabolism.

22 January 2020 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
TNTamás Németh
Tamás Németh
MSMarkus Sperandio
Markus Sperandio
AMAttila Mócsai
Attila Mócsai

1 November 1994 in Circulation Research
Verified
Journal Article
Closed access
PDF file
APA R Pries
A R Pries
TSTimothy W. Secomb
Timothy W. Secomb
TGT Gessner
T Gessner
MSM B Sperandio
M B Sperandio
JGJ F Gross
J F Gross
PGP Gaehtgens
P Gaehtgens
Resistance to blood flow through peripheral vascular beds strongly influences cardiovascular function and transport to tissue. For a given vascular architecture, flow resistance is determined by the rheological behavior of blood flowing through microvessels. A new approach for calculating the contribution of blood rheology to microvascular flow resistance is presented. Morphology (diameter and length), flow velocity, hematocrit, and topological position were determined for all vessel segments (up to 913) of terminal microcirculatory networks in the rat mesentery by intravital microscopy. Flow velocity and hematocrit were also predicted from mathematical flow simulations, in which the assumed dependence of flow resistance on diameter, hematocrit, and shear rate was optimized to minimize the deviation between measured and predicted values. For microvessels with diameters below approximately 40 microns, the resulting flow resistances are markedly higher and show a stronger dependence on hematocrit than previously estimated from measurements of blood flow in narrow glass tubes. For example, flow resistance in 10-microns microvessels at normal hematocrit is found to exceed that of a corresponding glass tube by a factor of approximately 4. In separate experiments, flow resistance of microvascular networks was estimated from direct measurements of total pressure drop and volume flow, at systemic hematocrits intentionally varied from 0.08 to 0.68. The results agree closely with predictions based on the above-optimized resistance but not with predictions based on glass-tube data. The unexpectedly high flow resistance in small microvessels may be related to interactions between blood components and the inner vessel surface that do not occur in smooth-walled tubes.

1 November 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MPMonika Pruenster
Monika Pruenster
TVThomas Vogl
Thomas Vogl
JRJohannes Roth
Johannes Roth
MSMarkus Sperandio
Markus Sperandio

22 February 2009 in Nature Medicine
Verified
Journal Article
Closed access
MMMarkus Moser
Markus Moser
MBMartina Bauer
Martina Bauer
SSStephan Schmid
Stephan Schmid
RRRaphael Ruppert
Raphael Ruppert
SSSarah Schmidt
Sarah Schmidt
RFReinhard Fässler
Reinhard Fässler

1 February 2008 in Circulation Research
Verified
Journal Article
Closed access
AZAlma Zernecke
Alma Zernecke
IBIlze Bot
Ilze Bot
YDYassin Djalali-Talab
Yassin Djalali-Talab
ESErdenechimeg Shagdarsuren
Erdenechimeg Shagdarsuren
KBKiril Bidzhekov
Kiril Bidzhekov
CWChristian Weber
Christian Weber
The CXC ligand (CXCL)12/CXC receptor (CXCR)4 chemokine–receptor axis controls hematopoiesis, organ development, and angiogenesis, but its role in the inflammatory pathogenesis of atherosclerosis is unknown. Here we show that interference with Cxcl12/Cxcr4 by a small-molecule antagonist, genetic Cxcr4 deficiency, or lentiviral transduction with Cxcr4 degrakine in bone marrow chimeras aggravated diet-induced atherosclerosis in apolipoprotein E-deficient ( Apoe −/− ) or LDL receptor–deficient ( Ldlr −/− ) mice. Chronic blockade of Cxcr4 caused leukocytosis and an expansion of neutrophils and increased neutrophil content in plaques, associated with apoptosis and a proinflammatory phenotype. Whereas circulating neutrophils were recruited to atherosclerotic lesions, depletion of neutrophils reduced plaque formation and prevented its exacerbation after blocking Cxcr4. Disrupting Cxcl12/Cxcr4 thus promotes lesion formation through deranged neutrophil homeostasis, indicating that Cxcl12/Cxcr4 controls the important contribution of neutrophils to atherogenesis in mice